Anthera Pharmaceuticals Inc (NASDAQ:ANTH) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: January 11, 2017
Having a price of $0.68, Anthera Pharmaceuticals Inc (NASDAQ:ANTH) traded -5.17% lower on the day. With the last close down -74.25% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.04% over the same period. Anthera Pharmaceuticals Inc has recorded a 50-day average of $1.57 and a two hundred day average of $2.63. Volume of trade was down over the average, with 1,608,480 shares of ANTH changing hands under the typical 1,781,120
Zacks Investment Research has upgraded Anthera Pharmaceuticals Inc (NASDAQ:ANTH) to Hold in a statement released on 1/11/2017.
Anthera Pharmaceuticals Inc has a 52 week low of $0.64 and a 52 week high of $4.90 The company’s market cap is currently $0.
About Anthera Pharmaceuticals Inc (NASDAQ:ANTH)
Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.